Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial

BACKGROUND: Schistosomiasis affects millions of people, yet treatment options are limited. The antimalarial Synriam (piperaquine 150 mg/arterolane 750 mg) and the anthelminthic moxidectin revealed promising antischistosomal properties in preclinical or clinical studies. METHODOLOGY: We conducted two...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS Negl Trop Dis
Hlavní autoři: Barda, Beatrice, Coulibaly, Jean T., Puchkov, Maxim, Huwyler, Jörg, Hattendorf, Jan, Keiser, Jennifer
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2016
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5026339/
https://ncbi.nlm.nih.gov/pubmed/27636542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0005008
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky